Skip to Main content Skip to Navigation
Master Thesis

Leucémie Myéloïde Chronique : rôle et apports du pharmacien d’officine dans la prise en charge des patients traités par inhibiteurs de tyrosine kinase BCR-ABL1

Abstract : Cancer is often managed in mutiple ways and its treatments are mumerous, based on validated protocols. Some patients can be treated at home, thanks to the emergeance of oral chemotherapy treatments, available in pharmacy. Although improving life’s quality, the use of these new treatments shows other issues such as compliance, management of side effects, and the continuity of care between hospital and home. In this context, the pharmacist is to be one of the main figure in the support of patients facing a strong moral and psychological impacting disease. The aim of this thesis is to focus on chronic myeloid leukemia (CML), a cancer in which bloodline cells multiplication and evolution is pathological and abnormal, due to a cytogenetic anomaly : a shortened and abnormal 22th chromosome carying BCR-ABL1 gene, responsible for the leukemogenesis. The development of BCR-ABL1 tyrosine kinase inhibitors (TKIs), available in pharmacies, had improved the survival of patients with CML. This work provides to the pharmacist some practical tools to help with the dispensing of such molecules, and the management of adverse effects and in the improvement of compliance of these TKI’s treated patients.
Document type :
Master Thesis
Complete list of metadata

https://dumas.ccsd.cnrs.fr/dumas-03215294
Contributor : Frédérique Gambade Connect in order to contact the contributor
Submitted on : Monday, May 3, 2021 - 11:44:22 AM
Last modification on : Wednesday, July 7, 2021 - 3:15:32 AM
Long-term archiving on: : Wednesday, August 4, 2021 - 6:52:50 PM

File

Pharmacie_2021_Sera.pdf
Files produced by the author(s)

Identifiers

  • HAL Id : dumas-03215294, version 1

Collections

Citation

Caroline Sera. Leucémie Myéloïde Chronique : rôle et apports du pharmacien d’officine dans la prise en charge des patients traités par inhibiteurs de tyrosine kinase BCR-ABL1. Sciences du Vivant [q-bio]. 2021. ⟨dumas-03215294⟩

Share

Metrics

Record views

24

Files downloads

26